Sign up Australia
Proactive Investors - Run By Investors For Investors

Daily CryptoCann™ Report: Coinbase may soon trade coins as securities; Aphria expands into Latin America and the Caribbean

The SEC and FINRA have approved acquisitions that will allow the exchange to operate as a broker-dealer
Daily CryptoCann™ Report: Coinbase may soon trade coins as securities; Aphria expands into Latin America and the Caribbean
The exchange is looking to add five new digital coins, including Cardano and Zcash

The Crypto Report

Popular cryptocurrency exchange Coinbase is one step closer to trading coins as securities.

The platform has been given the okay by US Securities and Exchange Commission and the Financial Industry Regulatory Authority to proceed with the acquisition of Keystone Capital Corp, Venovate Marketplace Inc and Digital Wealth LLC, according to a Bloomberg report.

The acquisitions will allow the firm to operate as a broker-dealer, offering security tokens while being subject to federal oversight.

The exchange is exploring allowing users to trade five new digital coins: Cardano, Basic Attention Token, Stellar, Zcash and Ox.

READ: Daily CryptoCann Report: IBM signs US$740mln blockchain deal with Australia’s government; Sweet Leaf loses all of its cannabis licenses

IBM Corp (NYSE:IBM) is also getting into the cryptocurrency game.

The tech giant is partnering with fintech start-up Stronghold to launch a cryptocurrency attached to the US dollar, according to a CNBC report.

Known as “Stronghold USD,” the digital token aims to reduce volatility by connecting itself to a government-backed currency.

The digital currency will be backed by Federal Deposit Insurance Corporation-insured US dollars and reserved will be held by Prime Trust, a blockchain-centric asset manager.

In other big-name tech news, Oracle Corporation (NYSE:ORCL) has launched its blockchain cloud service.

Known as the Oracle Blockchain Cloud Service, the platform is designed to track transactions and goods through global supply chains, as per Oracle’s press release.

“Blockchain promises to be one of the most transformative technologies of our generation,” said Amit Zavery, executive vice president of Oracle Cloud Platform.

Arab Jordan Investment Bank, CargoSmart, Indian Oil and TradeFin have adopted an earlier version of the service.

The Cann Report

Up north, Aphria Inc (TSX:APH, OTCMKTS:APHQF) is expanding into Latin America and the Caribbean.

The Canadian cannabis company announced plans to acquire assets in Colombia, Argentina, Jamaica and Brazil through a share purchase agreement with Scythian Biosciences Inc, as per a company press release.

Aphria will acquire 100% of the shares of LATAM Holdings Inc, a subsidiary of Scythian, for an undisclosed price.

Shares of the Ontario-based company were down more than 2.5% to C$10.63 in Tuesday afternoon trading.

READ: Crop Infrastructure Corp tenant at The Park in Washington state expects harvest within six weeks

Back in the States, a Canadian cannabis company is expanding into the Nevada market.

C21 Investments Inc (CNSX:CXXI) is making its latest move into the US marijuana market through its US$50mln acquisition of Silver State Relief and Silver State Cultivation.

Last month, the Vancouver-based company acquired Swell Companies, a marijuana extraction company in Oregon.

The company said it plans to spend an additional US$10mln on expansion into Nevada.

Shares of C21 fell more than 10% to C$2.05 in Tuesday afternoon trading.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full APH profile View Profile

Aphria Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use